Role of the nicotinic receptor β4 subunit in the antidepressant activity of novel N,6-dimethyltricyclo[5.2.1.02,6]decan-2-amine enantiomers

Neuroscience Letters

Volumn 553, Issue , 2013, Pages 186-190

  Targowska Duda, Katarzyna M ^a   Jozwiak, Krzysztof ^a   Arias, Hugo R ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b PLLC   (United States)

Author keywords

4 Subunit; Antidepressants; Forced swim test; Knock out mice; Nicotinic acetylcholine receptors

Indexed keywords

ANTIDEPRESSANT AGENT; N,6 DIMETHYLTRICYCLO[5.2.1.0 2,6 ]DECAN 2 AMINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BETA4; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENANTIOMER; FEMALE; FORCED SWIMMING TEST; KNOCKOUT MOUSE; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE;

ANTIDEPRESSANTS; FORCED SWIM TEST; KNOCK-OUT MICE; NICOTINIC ACETYLCHOLINE RECEPTORS; Β4 SUBUNIT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRIDGED COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, KNOCKOUT; MUTATION; NERVE TISSUE PROTEINS; PROTEIN SUBUNITS; RECEPTORS, NICOTINIC; SEX FACTORS; STEREOISOMERISM; STRESS, PSYCHOLOGICAL; SWIMMING;

EID: 84884403721     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.08.036     Document Type: Article

References (35)

1. Arias H.R., Bhumireddy P., Bouzat C. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int. J. Biochem. Cell. Biol. 2006, 38:1254-1276.
2. Arias H.R. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?. Int. J. Biochem. Cell Biol. 2009, 41:2098-2108.
3. Shytle R.D., Sheehan D.V., Sanberg P.R., Arias H.R. Neuronal nicotinic receptors as therapeutic targets for mood disorders. Pharmacology of Nicotinic Acetylcholine Receptors from the Basic and Therapeutic Perspectives 2011, 187-198. Research Signpost, Kerala, India.
4. Mineur Y.S., Picciotto M.R. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol. Sci. 2010, 31:580-586.
5. Picciotto M.R., Corrigall W.A. Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J. Neurosci. 2002, 22:3338-3341.
6. Glassman A.H., Helzer J.E., Covey L.S., Cottler L.B., Stetner F., Tipp J.E., Johnson J. Smoking, smoking cessation, and major depression. JAMA 1990, 264:1546-1549.
7. Popik P., Kozela E., Krawczyk M. Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. Br. J. Pharmacol. 2003, 139:1196-1202.
8. Vieyra-Reyes P., Venebra-Munoz A., Rivas-Santiago B., Garcia-Garcia F. Nicotine as an antidepressant and regulator of sleep in subjects with depression. Rev. Neurol. 2009, 49:661-667.
9. Caldarone B.J., Harrist A., Cleary M.A., Beech R.D., King S.L., Picciotto M.R. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol. Psychiatry 2004, 56:657-664.
10. Quick M.W., Ceballos R.M., Kasten M., McIntosh J.M., Lester R.A. α3β4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons. Neuropharmacology 1999, 38:769-783.
11. Grady S.R., Moretti M., Zoli M., Marks M.J., Zanardi A., Pucci L., Clementi F., Gotti C. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the α3β4> and α3β3β4> subtypes mediate acetylcholine release. J. Neurosci. 2009, 29:2272-2282.
12. Millar N.S., Gotti C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 2009, 56:237-246.
13. Baldwin P.R., Alanis R., Salas R. The role of the habenula in nicotine addiction. J. Addict. Res. Ther. 2011, S1.
14. Mineur Y.S., Obayemi A., Wigestrand M.B., Fote G.M., Calarco C.A., Li A.M., Picciotto M.R. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3573-3578.
15. Hikosaka O. The habenula: from stress evasion to value-based decision-making. Nat. Rev. Neurosci. 2010, 11:503-513.
16. Ranft K., Dobrowolny H., Krell D., Bielau H., Bogerts B., Bernstein H.G. Evidence for structural abnormalities of the human habenular complex in affective disorders but not in schizophrenia. Psychol. Med. 2010, 40:557-567.
17. Sartorius A., Henn F.A. Deep brain stimulation of the lateral habenula in treatment resistant major depression. Med. Hypotheses 2007, 69:1305-1308.
18. Salas R., Pieri F., Fung B., Dani J.A., De Biasi M. Altered anxiety-related responses in mutant mice lacking the β4 subunit of the nicotinic receptor. J. Neurosci. 2003, 23:6255-6263.
19. Salas R., Cook K.D., Bassetto L., De Biasi M. The α3 and β4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice. Neuropharmacology 2004, 47:401-407.
20. Salas R., Pieri F., De Biasi M. Decreased signs of nicotine withdrawal in mice null for the β4 nicotinic acetylcholine receptor subunit. J. Neurosci. 2004, 24:10035-10039.
21. Popik P., Krawczyk M., Kos T., Nalepa I., Kowalska M., Witarski T., Antkiewicz-Michaluk L., Vetulani J. Nicotine produces antidepressant-like actions: behavioral and neurochemical evidence. Eur. J. Pharmacol. 2005, 515:128-133.
22. Radhakrishnan R., Escobar L., Santamaría A., Arias H.R. The 4 nicotinic receptor subunit modulates the chronic antidepressant activity mediated by bupropion. Neurosci. Lett. 2013, pii: S0304-3940(13)00728-3. 10.1016/j.neulet.2013.08.009.
23. Salas R., Sturm R., Boulter J., De Biasi M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J. Neurosci. 2009, 29:3014-3018.
24. Harmer C.J., O'Sullivan U., Favaron E., Massey-Chase R., Ayres R., Reinecke A., Goodwin G.M., Cowen P.J. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am. J. Psychiatry. 2009, 166:1178-1184.
25. Hajszan T., MacLusky N.J., Leranth C. Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. Eur. J. Neurosci. 2005, 21:1299-1303.
26. Guirado R., Sanchez-Matarredona D., Varea E., Crespo C., Blasco-Ibanez J.M., Nacher J. Chronic fluoxetine treatment in middle-aged rats induces changes in the expression of plasticity-related molecules and in neurogenesis. BMC Neurosci. 2012, 13:5.
27. Semba J., Wakuta M. Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion. Psychiatry Clin. Neurosci. 2008, 62:435-441.
28. Grant M.M., Weiss J.M. Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol. Psychiatry 2001, 49:117-129.
29. Sodero A.O., Valdomero A., Cuadra G.R., Ramirez O.A., Orsingher O.A. Locus coeruleus activity in perinatally protein-deprived rats: effects of fluoxetine administration. Eur. J. Pharmacol. 2004, 503:35-42.
30. Tanti A., Belzung C. Hippocampal neurogenesis: a biomarker for depression or antidepressant effects? Methodological considerations and perspectives for future research. Cell Tissue Res. 2013, 10.1007/s00441-013-1612-z.
31. Nishikawa T., Fage D., Scatton B. Evidence for, and nature of, the tonic inhibitory influence of habenulointerpeduncular pathways upon cerebral dopaminergic transmission in the rat. Brain Res. 1986, 373:324-336.
32. Lester D.B., Rogers T.D., Blaha C.D. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 2010, 16:137-162.
33. Kokras N., Dalla C., Papadopoulou-Daifoti Z. Sex differences in pharmacokinetics of antidepressants. Expert Opin. Drug Metab. Toxicol. 2011, 7:213-226.
34. Franconi F., Campesi I., Occhioni S., Antonini P., Murphy M.F. Sex and gender in adverse drug events, addiction, and placebo. Handb. Exp. Pharmacol. 2012, 214:107-126.
35. Okiishi C.G., Paradiso S., Robinson R.G. Gender differences in depression associated with neurologic illness: clinical correlates and pharmacologic response. J. Gend. Specif. Med. 2001, 4:65-72.